New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma.
作者信息
Montironi Carla, Montal Robert, Llovet Josep M
机构信息
Liver Cancer Translational Research Laboratory Institut d'Investigacions Biomèdiques August Pi I Sunyer-Hospital Clinic, Liver Unit, Universitat de Barcelona Barcelona Catalonia Spain.
Mount Sinai Liver Cancer Program, Department of Liver Diseases, Icahn School of Medicine at Mount Sinai New York NY.
出版信息
Clin Liver Dis (Hoboken). 2019 Sep 2;14(2):56-61. doi: 10.1002/cld.796. eCollection 2019 Aug.
Abstract
摘要
相似文献
1
New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma.
Clin Liver Dis (Hoboken). 2019 Sep 2;14(2):56-61. doi: 10.1002/cld.796. eCollection 2019 Aug.
2
[Systemic chemotherapy of hepatocellular carcinoma].
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1584-8.
3
[New progress in the first-line treatment of advanced hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi. 2024 Feb 20;32(2):173-179. doi: 10.3760/cma.j.cn501113-20231114-00193.
4
Systemic Therapy in Metastatic Hepatocellular Carcinoma.
Curr Gastroenterol Rep. 2022 May;24(5):65-71. doi: 10.1007/s11894-022-00842-9. Epub 2022 Apr 13.
5
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.
Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21.
6
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
Int J Clin Oncol. 2022 Jul;27(7):1110-1119. doi: 10.1007/s10147-022-02166-0. Epub 2022 May 8.
7
[Hepatocellular carcinoma].
Gan To Kagaku Ryoho. 2010 Jul;37(7):1219-23.
8
[New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Korean J Gastroenterol. 2019 Jan 25;73(1):10-15. doi: 10.4166/kjg.2019.73.1.10.
9
Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480.
10
Hepatocellular carcinoma.
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.
引用本文的文献
1
Antiproliferative Activity of -Acylhydrazone Derivative on Hepatocellular Carcinoma Cells Involves Transcriptional Regulation of Genes Required for G2/M Transition.
Biomedicines. 2024 Apr 18;12(4):892. doi: 10.3390/biomedicines12040892.
2
Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival.
Eur J Pharmacol. 2023 Oct 15;957:176034. doi: 10.1016/j.ejphar.2023.176034. Epub 2023 Aug 29.
3
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.
Chin Med J (Engl). 2021 Dec 1;134(24):2911-2921. doi: 10.1097/CM9.0000000000001888.
4
Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma.
Front Pharmacol. 2020 Aug 13;11:1264. doi: 10.3389/fphar.2020.01264. eCollection 2020.
5
Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Molecules. 2020 Jun 20;25(12):2856. doi: 10.3390/molecules25122856.
本文引用的文献
1
Molecular therapies and precision medicine for hepatocellular carcinoma.
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4.
2
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
3
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
4
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
J Clin Oncol. 2018 Jul 1;36(19):1913-1921. doi: 10.1200/JCO.2017.76.0892. Epub 2018 Mar 2.
5
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
6
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
7
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
J Hepatol. 2017 Nov;67(5):999-1008. doi: 10.1016/j.jhep.2017.06.026. Epub 2017 Jul 4.
8
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
9
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
10
Hepatocellular carcinoma.
Nat Rev Dis Primers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18.
Zotero 插件